Nanodelivery of Cerebrolysin and Rearing in Enriched Environment Induce Neuroprotective Effects in a Preclinical Rat Model of Parkinson’s Disease

被引:0
|
作者
C. Requejo
J. A. Ruiz-Ortega
H. Cepeda
A. Sharma
H. S. Sharma
A. Ozkizilcik
R. Tian
H. Moessler
L. Ugedo
J. V. Lafuente
机构
[1] University of the Basque Country (UPV/EHU),LaNCE, Department of Neuroscience
[2] University of the Basque Country (UPV/EHU),Department of Pharmacology
[3] Uppsala University,International Experimental CNS Injury & Repair
[4] Uppsala University Hospital,Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine
[5] Uppsala University,Department of Biomedical Engineering
[6] University of Arkansas,Department of Chemistry & Biochemistry
[7] University of Arkansas,Drug Discovery & Develop
[8] Ever Neuro Pharma,Nanoneurosurgery Group
[9] BioCruces Health Research Institute,Faculty of Health Science
[10] Universidad Autónoma de Chile,undefined
来源
Molecular Neurobiology | 2018年 / 55卷
关键词
Parkinson’s disease; 6-OHDA; Preclinical stage; Nanowired cerebrolysin; Enriched environment; Neuroprotection;
D O I
暂无
中图分类号
学科分类号
摘要
Rearing in enriched environment (EE) improves the recuperation in animal models of Parkinson’s disease (PD). Administration of TiO2-nanowired cerebrolysin (CBL) could represent an additional strategy to protect or repair the nigrostriatal system. This study aims to explore morphofunctional and biochemical changes in a preclinical stage of PD testing the synergistic efficiency of combining both strategies, housing in EE, and nanodelivery of CBL. Sprague-Dawley male rats receiving intrastriatally 6-hydroxydopamine after a short evolution time were segregated into CBL group (rats receiving nanowired CBL), EE group (rats housed in EE), CBL + EE group (rats housed in EE and receiving nanowired CBL), and control group (rats without additional treatment). Prodromic stage and treatment effects were characterized by the presence of motor symptoms (amphetamine-induced rotational behavior test). Tyrosine hydroxylase (TH) immunohistochemistry and Western blot (p-Akt/Akt and p-ERK/ERK 1/2 as survival markers and caspase-3 as apoptotic marker) were performed in striatum and SN. A decrease in motor symptoms was shown by rats receiving CBL. EE monitoring cages revealed that rats from CBL + EE group showed more significant number of laps in the wheel than EE group. In SN, CBL + EE group also presented the highest neuronal density. Moreover, p-Akt/Akt and p-ERK/ERK 1/2 ratio was significant higher and caspase-3 expression was lower in CBL + EE group. In conclusion, the combination of CBL and EE provided evidence of neuoprotective-neurorestorative mechanisms by which this combined strategy promoted morphofunctional improvement by activation of survival pathways after dopamine depletion in a preclinical model of PD.
引用
收藏
页码:286 / 299
页数:13
相关论文
共 50 条
  • [31] The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer's disease are associated with improved behavioral performance
    Rockenstein, E
    Adame, A
    Mante, M
    Moessler, H
    Windisch, M
    Masliah, E
    JOURNAL OF NEURAL TRANSMISSION, 2003, 110 (11) : 1313 - 1327
  • [32] A promising therapeutic potential of cerebrolysin in 6-OHDA rat model of Parkinson's disease
    Noor, Neveen A.
    Mohammed, Haitham S.
    Mourad, Iman M.
    Khadrawy, Yasser A.
    Ezz, Heba S. Aboul
    LIFE SCIENCES, 2016, 155 : 174 - 179
  • [33] Neuroprotective and neurogeneic effects of embryonic neural stem cell grafts in a rat model of Parkinson's disease
    Yasuhara, T
    Matsukawa, N
    Hara, K
    Yu, G
    Xu, L
    Yoon, YI
    Date, I
    Kim, SU
    Borlongan, CV
    EXPERIMENTAL NEUROLOGY, 2006, 198 (02) : 596 - 596
  • [34] Neuroprotective effects of VEGF-C in the 6-OHDA rat model of Parkinson's disease
    Piltonen, M.
    Planken, A.
    Leskela, O.
    Saarma, M.
    Mannisto, P. T.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S92 - S92
  • [35] Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
    Chen, YiMei
    Zhang, Yanfang
    Li, Lin
    Hoelscher, Christian
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 768 : 21 - 27
  • [36] Exercise exerts neuroprotective effects on Parkinson's disease model of rats
    Tajiri, Naoki
    Yasuhara, Takao
    Shingo, Tetsuro
    Kondo, Akihiko
    Yuan, Wenji
    Kadota, Tomohito
    Wang, Feifei
    Baba, Tanefumi
    Tayra, Judith Thomas
    Morimoto, Takamasa
    Jing, Meng
    Kikuchi, Yoichiro
    Kuramoto, Satoshi
    Agari, Takashi
    Miyoshi, Yasuyuki
    Fujino, Hidemi
    Obata, Futoshi
    Takeda, Isao
    Furuta, Tomohisa
    Date, Isao
    BRAIN RESEARCH, 2010, 1310 : 200 - 207
  • [37] Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease
    Bahdoudi, Seyma
    Ghouili, Ikram
    Hmiden, Mansour
    do Rego, Jean-Luc
    Lefranc, Benjamin
    Leprince, Jerome
    Chuquet, Julien
    do Rego, Jean-Claude
    Marcher, Ann-Britt
    Mandrup, Susanne
    Vaudry, Hubert
    Tonon, Marie-Christine
    Amri, Mohamed
    Masmoudi-Kouki, Olfa
    Vaudry, David
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2018, 75 (11) : 2075 - 2091
  • [38] Neuroprotective Effects of Cryptotanshinone in a Direct Reprogramming Model of Parkinson's Disease
    Lee, Joo-Eun
    Sim, Hyuna
    Yoo, Hee Min
    Lee, Minhyung
    Baek, Aruem
    Jeon, Young-Joo
    Seo, Kang-Sik
    Son, Mi-Young
    Yoon, Joo Seog
    Kim, Janghwan
    MOLECULES, 2020, 25 (16):
  • [39] Neuroprotective effects of rasagiline in a double lesion model of Parkinson's disease
    Granholm, A. -C. E.
    Cantwell, K.
    Umphlet, C.
    Ledreux, A.
    Boger, H. A.
    MOVEMENT DISORDERS, 2014, 29 : S12 - S13
  • [40] Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson's Disease
    Giuliano, Claudio
    Francavilla, Miriam
    Ongari, Gerardo
    Petese, Alessandro
    Ghezzi, Cristina
    Rossini, Nora
    Blandini, Fabio
    Cerri, Silvia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)